RFX3

Across TCGA pan-cancer cohorts, RFX3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RFX3 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RFX3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RFX3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where RFX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.959	0.395	<.001	80	view →
PDAC	DFS	Tertile	III,IV	0.808	0.155	.049	12	view →
HNSC	DFS	Quartile	II,III,IV	0.876	0.532	.028	6	view →
LUAD	DFS	Quartile	II,III,IV	0.929	0.714	.039	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RFX3–CCRCC (DFS)

Open the CCRCC breakdown →